Skip to main content

Ana Barreira Diaz

Institutions of which they are part

Liver Diseases
Vall Hebron Institut de Recerca

Ana Barreira Diaz

Institutions of which they are part

Liver Diseases
Vall Hebron Institut de Recerca

Projects

Impact of HLA haplotypes and HDV viremia in developing of clinical events and quality of life of patients with chronic hepatitis delta.

IP: Maria Buti Ferret
Collaborators: Maria Jose Herrero Mata, Ana Barreira Diaz, Maria del Mar Riveiro Barciela, Jordi Llaneras Artigues, Adriana Palom Agusti
Funding agency: Instituto de Salud Carlos III
Funding: 117370
Reference: PI20/01692
Duration: 01/01/2021 - 30/06/2025

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

Laura Murillo Sanjuán

Laura Murillo Sanjuán

Predoctoral researcher
Childhood Cancer and Blood Disorders
Read more
Martinez  Lopez, Maria Pilar

Martinez Lopez, Maria Pilar

Research assistant
General Surgery
Read more
Claudia Maria Herrera de Guise

Claudia Maria Herrera de Guise

Postdoctoral researcher
Physiology and Pathophysiology of the Digestive Tract
Read more
Marín Garcia, Antonio

Marín Garcia, Antonio

Predoctoral researcher
Physiology and Pathophysiology of the Digestive Tract
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.